RxSight, Inc.
NASDAQ:RXST · NASDAQ Global Market
+$0.05 today
Vol 0.94M · Avg 0.80M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:RXST · Revenue to Net Income
Key Ratios
Analysis
$127.5M of revenue converted into -$46.6M of net income for the selected period. Gross margin is 77.1% and net margin is -36.7%, showing how much revenue survives after costs and taxes. EPS is $-1.13, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $134.5M -3.9% | $139.9M +57.1% | $89.1M +81.8% | $49.0M +116.9% | $22.6M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $31.5M -23.2% | $41.0M +16.1% | $35.3M +27.6% | $27.7M +53.1% | $18.1M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $103.0M +4.1% | $98.9M +84.0% | $53.8M +152.1% | $21.3M +372.2% | $4.5M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 76.6% +5.9pp | 70.7% +10.4pp | 60.4% +16.8pp | 43.5% +23.5pp | 20.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $38.5M +12.2% | $34.4M +18.3% | $29.1M +11.8% | $26.0M +6.0% | $24.5M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $112.6M +11.1% | $101.4M +35.6% | $74.8M +27.5% | $58.7M +78.8% | $32.8M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $151.2M +11.3% | $135.8M +30.8% | $103.8M +22.7% | $84.6M +47.7% | $57.3M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $0 -100.0% | $3.6M -14.6% | $4.2M +5.5% | $4.0M +0.9% | $4.0M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$38.8M -63.5% | -$23.8M +42.1% | -$41.0M +29.0% | -$57.8M -40.9% | -$41.0M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -28.9% -11.9pp | -17.0% +29.1pp | -46.1% +71.8pp | -117.9% +63.6pp | -181.5% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$48.2M -30.7% | -$36.9M +26.4% | -$50.1M +20.9% | -$63.3M -19.9% | -$52.8M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -35.8% -9.5pp | -26.3% +29.9pp | -56.2% +73.0pp | -129.2% +104.4pp | -233.6% | 16.6% | 24.1% | 22.0% |
| Interest Income | $2.5M -73.5% | $9.5M +44.1% | $6.6M +333.4% | $1.5M +2709.3% | $54.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $40.0K +90.5% | $21.0K -99.4% | $3.3M -33.1% | $4.9M +34.3% | $3.7M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $9.3M -1.5% | $9.5M +531.5% | $1.5M +143.7% | -$3.4M -183.5% | $4.1M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$38.9M -41.9% | -$27.4M +43.6% | -$48.6M +27.2% | -$66.7M -37.1% | -$48.7M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -28.9% -9.3pp | -19.6% +35.0pp | -54.5% +81.7pp | -136.2% +79.3pp | -215.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $66.0K +32.0% | $50.0K +150.0% | $20.0K +122.2% | $9.0K +12.5% | $8.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$38.9M -41.8% | -$27.5M +43.5% | -$48.6M +27.2% | -$66.8M -37.1% | -$48.7M | $4.9B | $4.8B | $4.7B |
| Net Margin | -29.0% -9.3pp | -19.6% +34.9pp | -54.6% +81.7pp | -136.2% +79.3pp | -215.5% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 -33.8% | -$1 +49.6% | -$1 +41.5% | -$2 -35.4% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 -33.8% | -$1 +49.6% | -$1 +41.5% | -$2 -35.4% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $41.2M +5.9% | $38.9M +12.8% | $34.5M +24.6% | $27.7M +1.1% | $27.4M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $41.2M +5.9% | $38.9M +12.8% | $34.5M +24.6% | $27.7M +1.1% | $27.4M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Butterfly Network, Inc.
NYSE:BFLY
$2.18B
Surmodics, Inc.
SRDX
$614.51M
Tactile Systems Technology, Inc.
NASDAQ:TCMD
$598.58M
Cerus Corporation
NASDAQ:CERS
$537.99M
NeuroPace, Inc.
NASDAQ:NPCE
$523.81M
OrthoPediatrics Corp.
NASDAQ:KIDS
$474.27M
Delcath Systems, Inc.
NASDAQ:DCTH
$405.63M
Semler Scientific, Inc.
SMLR
$310.75M
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
$307.13M
Treace Medical Concepts, Inc.
NASDAQ:TMCI
$267.60M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does RXST generate?
RxSight, Inc. (RXST) reported $134.48M of revenue in fiscal 2025.
Is RXST profitable?
RxSight, Inc. (RXST) reported -$38,943,000.00 of net income, with a net margin of -29.0%.
Explore More
Continue the stock analysis
Jump to another research area for this company.